Ergothioneine is a naturally occurring sulfur-containing amino acid and potent antioxidant that is primarily obtained through dietary sources like mushrooms and absorbed via the highly specific OCTN1 (ETT) transporter. It acts as a cytoprotective agent by accumulating in tissues subject to high oxidative stress, where it helps protect DNA, proteins, and lipids from damage while supporting mitochondrial function.

Overview

Ergothioneine (EGT, 2-mercaptohistidine trimethylbetaine) is a unique sulfur-containing amino acid first isolated from ergot fungus (Claviceps purpurea) in 1909. Unlike glutathione and other endogenous antioxidants, ergothioneine cannot be synthesized by plants or animals and must be obtained through diet—primarily from mushrooms (especially king oyster, shiitake, and porcini), with smaller amounts in kidney, liver, and certain beans. The existence of a dedicated, high-affinity transporter, OCTN1 (SLC22A4), encoded across virtually all animal kingdoms, strongly suggests an essential physiological role that has been conserved over evolution.

Ergothioneine accumulates preferentially in tissues with high oxidative stress exposure, including erythrocytes, bone marrow, liver, kidney, seminal fluid, and the lens of the eye, reaching millimolar intracellular concentrations. Its antioxidant mechanism is distinct from other biological thiols: the thione tautomer predominates at physiological pH, making ergothioneine highly resistant to auto-oxidation (unlike cysteine or glutathione) while still capable of scavenging hydroxyl radicals, hypochlorous acid, peroxynitrite, and singlet oxygen. It also chelates divalent metal ions (Cu²⁺, Fe²⁺), preventing Fenton chemistry, and protects mitochondrial DNA and proteins from oxidative damage.

Epidemiological data has generated significant interest in ergothioneine as a potential longevity vitamin. Studies show that blood ergothioneine levels decline with age and are significantly lower in individuals with mild cognitive impairment, Parkinson's disease, cardiovascular disease, and frailty. The Singapore Longitudinal Ageing Study found that higher plasma ergothioneine was associated with reduced risk of cognitive decline and dementia. In 2023, the European Food Safety Authority (EFSA) approved synthetic ergothioneine as a novel food ingredient, and it is increasingly available as a dietary supplement, with typical doses ranging from 5 to 25 mg daily.

Mechanism of Action

Cellular Uptake via OCTN1

Ergothioneine (ET) is a histidine-derived thiol amino acid synthesized exclusively by certain fungi, actinobacteria, and cyanobacteria. Mammals acquire it solely through diet and concentrate it intracellularly via the highly specific transporter OCTN1 (SLC22A4). OCTN1 expression is particularly high in erythrocytes, bone marrow, liver, kidney, and the central nervous system, suggesting an evolved physiological role for ET in these tissues (PMID: 22067612).

Antioxidant Mechanisms

ET exists predominantly as a thione tautomer at physiological pH, making it resistant to auto-oxidation — unlike glutathione, it does not readily form disulfides. It directly scavenges hydroxyl radicals, hypochlorous acid (HOCl), peroxynitrite (ONOO-), and singlet oxygen with high rate constants. ET chelates divalent metal ions (Cu2+, Fe2+), preventing Fenton reaction-mediated hydroxyl radical generation. It also protects iron-sulfur cluster enzymes such as aconitase from oxidative inactivation (PMID: 29364803).

Mitochondrial & Cytoprotective Pathways

ET accumulates in mitochondria where it preserves complex I and complex III activity under oxidative stress. It activates the Nrf2/ARE (nuclear factor erythroid 2-related factor 2 / antioxidant response element) signaling pathway, upregulating endogenous antioxidant enzymes including heme oxygenase-1 (HO-1), glutathione peroxidase (GPx), and NAD(P)H quinone dehydrogenase 1 (NQO1). ET also inhibits NF-kB nuclear translocation, reducing transcription of pro-inflammatory cytokines TNF-alpha, IL-1beta, and IL-6 (PMID: 31905867).

Anti-Inflammatory & Neuroprotective Effects

In microglia, ET suppresses LPS-induced iNOS expression and nitric oxide production. It inhibits NLRP3 inflammasome activation by reducing mitochondrial ROS. In neuronal models, ET protects against beta-amyloid and cisplatin-induced toxicity by maintaining mitochondrial membrane potential and preventing cytochrome c release (PMID: 32024867).

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Ergothioneine

Common Side Effects

• Generally very well tolerated with few reported side effects at typical supplement doses (5-30 mg/day)
• Mild gastrointestinal discomfort (bloating, mild nausea) reported occasionally
• Rare headache during initial supplementation
• Slight metallic or sulfurous aftertaste with some formulations
• Mild changes in urine odor (sulfur compound)

Serious Adverse Effects

• No serious adverse effects documented in published human clinical trials at doses up to 25 mg/day for 12 weeks
• Theoretical concern of interference with oxidative burst in immune cells at very high doses (immunosuppressive potential), though not observed clinically
• Extremely limited long-term safety data beyond 12 weeks in humans
• No genotoxicity, mutagenicity, or carcinogenicity observed in preclinical studies
• Received GRAS (Generally Recognized as Safe) status from FDA for use in food and supplements

Contraindications

• Known hypersensitivity to ergothioneine or mushroom-derived products
• Caution in patients on immunosuppressive therapy (theoretical immunomodulatory effects)
• No absolute contraindications established for short-term use at recommended doses
• Pregnancy and lactation: avoid due to insufficient safety data
• Not recommended for children under 18 due to lack of pediatric studies

Drug Interactions

• Antioxidant supplements (NAC, glutathione, vitamin C): Potential additive antioxidant effects; generally safe but high combined doses may theoretically blunt beneficial oxidative signaling
• Immunosuppressants: Theoretical interaction based on ergothioneine's cytoprotective properties in immune cells; clinical significance unknown
• Chemotherapy agents: May protect healthy cells but could theoretically reduce efficacy of ROS-dependent cytotoxic drugs; avoid concurrent use without oncologist guidance
• Iron supplements: Ergothioneine chelates certain metal ions; may reduce iron bioavailability if taken simultaneously
• OCTN1 transporter substrates: Ergothioneine is transported via OCTN1; may compete with other substrates for cellular uptake

Population-Specific Considerations

• Elderly: Potentially beneficial population due to age-related decline in ergothioneine levels; well tolerated in limited studies
• Pediatric: No safety data; not recommended
• Pregnant/Lactating: No human reproductive toxicity data; avoid as precaution despite favorable preclinical profile
• Renal impairment: Ergothioneine accumulates in tissues with high OCTN1 expression; pharmacokinetics in renal failure unknown; use cautiously
• Mushroom allergy: Supplemental ergothioneine is typically synthetic or fermentation-derived, but verify source if mushroom-allergic
• Note: Ergothioneine has an excellent short-term safety profile but long-term human data remains limited; regulatory status varies by country

Pharmacokinetic Profile